Filter Results:
(68)
Show Results For
- All HBS Web (119)
- Faculty Publications (45)
Show Results For
- All HBS Web (119)
- Faculty Publications (45)
Sort by
- 24 Sep 2007
- Research & Ideas
The FDA: What Will the Next 100 Years Bring?
responsible for the safety and effectiveness of prescription drugs, biologics (biotech products derived from living sources such as cells), over-the-counter medicines, medical devices, cosmetics, nutritional supplements, and all food... View Details
- 02 Aug 2004
- Research & Ideas
Health Care Research and Prospects
As is clear to anyone who pays medical insurance premiums or has undergone any kind of medical procedure, the business of health care is an expensive one. The technology is expensive. The research is... View Details
- 01 Nov 2024
- In Practice
Layoffs Surging in a Strong Economy? Advice for Navigating Uncertain Times
decision about entrepreneurship Starting your own company after a layoff is a significant decision. While it may seem like an opportune time, research suggests there are some important considerations. “Entrepreneurs coming from high-tech sectors such as View Details
- 11 Nov 2015
- Working Paper Summaries
Public R&D Investments and Private-sector Patenting: Evidence from NIH Funding Rules
- 17 Mar 2009
- First Look
First Look: March 17, 2009
care services are internationally renowned for quality. In 2008, The Clinic is restructuring the organization into teams defined around patient needs, rather than traditional medical specialties. "Patients First!" takes shape as... View Details
Keywords: Martha Lagace
- 21 Apr 2014
- Research & Ideas
Bio-Piracy: When Western Firms Usurp Eastern Medicine
art. By 2005, the Traditional Knowledge Digital Library (TKDL) spanned more than 34 million pages of Indian literature, including herbal formulations from the Unani, Yoga, Ayurveda, and Siddha medical systems. Texts that spanned centuries... View Details
- 12 Sep 2006
- First Look
First Look: September 12, 2006
a not-for-profit research center at the Harvard Medical School (HMS). The center was started in late 2000 with a gift of $37.5 million from an anonymous donor. Its mandate was to conduct research that could lead to actual treatments for... View Details
Keywords: Sean Silverthorne
- September 2008
- Background Note
Background on the Technology of Molecular Diagnostics
By: Regina E. Herzlinger and Jason Sanders
To be used as background reading for the "EXACT Sciences Corp.: Commercializing a Diagnostic Test" and "Diagnostic Genomics" cases, HBS nos. 308-090 and 309-040. View Details
Herzlinger, Regina E., and Jason Sanders. "Background on the Technology of Molecular Diagnostics." Harvard Business School Background Note 309-050, September 2008.
- 03 Feb 2009
- First Look
First Look: February 3, 2009
behavior, distorted risk preferences, corrosion of organizational culture, and reduced intrinsic motivation. Rather than dispensing goal setting as a benign, over-the-counter treatment for motivation, managers and scholars need to conceptualize goal setting as a... View Details
Keywords: Martha Lagace
- 08 Dec 2003
- Research & Ideas
Why Europe Lags in Pharmaceuticals and Biotech
suggest that the European consumer's thirst for medical knowledge is greater than even what is seen in the U.S. "As a marketer, I want an informed patient," he said. Maisonrouge urged students to look for opportunities with... View Details
- 03 Dec 2001
- Research & Ideas
Healthcare Conference Looks At Ailing Industry
Mixing Risk And Reward The basic model that the biotechnology industry has followed for over twenty years is also changing, and for the better, according to panelists at a session titled "Will Equal Biotechnology-Pharma Partnerships... View Details
- 22 Sep 2020
- Research & Ideas
Recessions Push Some Entrepreneurs to Launch Too Soon
an associate professor at University of Lausanne, studied 3,025 US founders from 2005 to 2012 and their 1,747 startups in the biotechnology and medical device sectors during previous economic downturns.... View Details
Keywords: by Sean Silverthorne
- 26 Jun 2000
- Research & Ideas
Presentation Round-Up
among scientists that was unprecedented in human genetics research. A professor of genetics and director of Harvard Medical School's Lipper Center for Computational Genetics, Church noted that his own computer experience dates back to... View Details
- 09 Apr 2012
- Research & Ideas
Who Sways the USDA on GMO Approvals?
on the process. On the other, it opens up the possibility that firms could capture these third-party actors instead—for example, drug companies influencing doctors with incentives for prescribing drugs or sponsoring medical conferences.... View Details
- 12 Mar 2013
- First Look
First Look: March 12
A. Arnaout Publication:Nature Biotechnology Abstract Advances in biotechnology have fueled the generation of unprecedented quantities of data across the life sciences. However, finding analysts who can... View Details
Keywords: Sean Silverthorne
- 18 Dec 2012
- First Look
First Look: December 18
Bias for Normal Science: Evidence from Randomized Medical Grant Proposal Evaluations Authors:Boudreau, Kevin J., Eva C. Guinan, Karim R. Lakhani, and Christoph Riedl Abstract Central to any innovation process is the evaluation of proposed... View Details
Keywords: Carmen Nobel
- 03 Nov 2015
- First Look
November 3, 2015
November 2015 Quarterly Journal of Economics Behavioral Hazard in Health Insurance By: Baicker, Katherine, Sendhil Mullainathan, and Joshua Schwartzstein Abstract—A fundamental implication of standard moral hazard models is overuse of low-value View Details
Keywords: Sean Silverthorne
- 06 Jun 2017
- First Look
First Look at New Research and Ideas: June 6, 2017
Pharmacyclics is a biotechnology company that had received FDA approval in late 2013 for its flagship asset Imbrivica (ibrutinib), a biologic treatment for chronic lymphocytic leukemia and two other even rarer blood malignancies. Entering... View Details
Keywords: Sean Silverthorne
- 23 Oct 2018
- First Look
New Research and Ideas, October 23, 2018
to market? Using data from the U.S. medical device industry, we find that pioneer (dis-)advantages in a market for technology setting are similar to those typically seen in product markets but different in some important respects. In... View Details
Keywords: Dina Gerdeman
- 12 May 2009
- First Look
First Look: May 12, 2009
Case 809-026 An executive from pharmaceutical company GSK must choose how much to integrate a recently acquired biotechnology firm, Sirtris. Moncef Slaoui, GSK's global head of R&D, championed the acquisition of Sirtris to gain access... View Details
Keywords: Martha Lagace